Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010)
Alnylam Pharmaceuticals (ALNY) posted Current Deferred Tax Assets of $1.9 million for Q3 2010, little changed on a QoQ basis from $1.9 million in Q2 2010.
Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010) Analysis & Trends
Alnylam Pharmaceuticals' Current Deferred Tax Assets history runs 2 years deep, the most recent figure standing at $1.9 million for Q3 2010.
- Quarterly Current Deferred Tax Assets changed N/A year-over-year to $1.9 million in Q3 2010, while the trailing twelve-month figure through Sep 2010 was $1.9 million (changed N/A YoY) and the FY2009 annual result came in at $1.9 million, changed N/A from the prior year.
- Current Deferred Tax Assets was $1.9 million for Q3 2010 at Alnylam Pharmaceuticals, roughly flat from $1.9 million in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $1.9 million in Q3 2010 and bottomed at $1.9 million in Q4 2009.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2010 | 1.94 Mn |
| Sep 30, 2010 | 1.94 Mn |
| Jun 30, 2010 | 1.94 Mn |
| Jun 30, 2010 | 1.94 Mn |
| Dec 31, 2009 | 1.94 Mn |
| Dec 31, 2009 | 1.94 Mn |